Adrian R Krainer
Overview
Explore the profile of Adrian R Krainer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
149
Citations
14149
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Voss D, Kral A, Sim G, Utama R, Lin K, Cizmeciyan C, et al.
J Biol Chem
. 2025 Feb;
:108345.
PMID: 39993527
Pyruvate kinase M isoform 2 (PKM2) is preferentially expressed in nearly all cancers. It primarily functions as the last enzyme in glycolysis, but has other reported non-canonical functions, including recruiting...
2.
Alsaloum M, Dib-Hajj S, Page D, Ruben P, Krainer A, Waxman S
Nat Rev Drug Discov
. 2025 Feb;
PMID: 39901031
Excitable cells - including neurons, muscle cells and cardiac myocytes - are unique in expressing high densities of voltage-gated sodium (Na) channels. This molecular adaptation enables these cells to produce...
3.
Yang X, Bhowmick K, Rao S, Xiang X, Ohshiro K, Amdur R, et al.
Cell Rep
. 2024 Sep;
43(9):114676.
PMID: 39217614
Obesity and fatty liver diseases-metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH)-affect over one-third of the global population and are exacerbated in individuals with reduced functional aldehyde...
4.
Maia-Silva D, Cunniff P, Schier A, Skopelitis D, Trousdell M, Moresco P, et al.
Nat Genet
. 2024 Jun;
56(7):1377-1385.
PMID: 38886586
The presence of basal lineage characteristics signifies hyperaggressive human adenocarcinomas of the breast, bladder and pancreas. However, the biochemical mechanisms that maintain this aberrant cell state are poorly understood. Here...
5.
Segovia D, Adams D, Hoffman N, Safaric Tepes P, Wee T, Cifani P, et al.
Proc Natl Acad Sci U S A
. 2024 May;
121(21):e2322974121.
PMID: 38743621
SRSF1 is the founding member of the SR protein family. It is required-interchangeably with other SR proteins-for pre-mRNA splicing in vitro, and it regulates various alternative splicing events. Dysregulation of...
6.
Wan L, Kral A, Voss D, Schafer B, Sudheendran K, Danielsen M, et al.
Nucleic Acid Ther
. 2024 May;
34(4):188-198.
PMID: 38716830
Aberrant alternative splicing is emerging as a cancer hallmark and a potential therapeutic target. It is the result of dysregulated or mutated splicing factors, or genetic alterations in splicing-regulatory -elements....
7.
Ishigami Y, Wong M, Marti-Gomez C, Ayaz A, Kooshkbaghi M, Hanson S, et al.
Nat Commun
. 2024 Feb;
15(1):1880.
PMID: 38424098
Drugs that target pre-mRNA splicing hold great therapeutic potential, but the quantitative understanding of how these drugs work is limited. Here we introduce mechanistically interpretable quantitative models for the sequence-specific...
8.
Xiang X, Bhowmick K, Shetty K, Ohshiro K, Yang X, Wong L, et al.
Genes Cancer
. 2024 Feb;
15():1-14.
PMID: 38323119
Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer worldwide but is often diagnosed at an advanced incurable stage. Yet, despite the urgent need for blood-based biomarkers...
9.
Wan L, Lin K, Rahman M, Ishigami Y, Wang Z, Jensen M, et al.
Cancer Discov
. 2023 Apr;
13(7):1678-1695.
PMID: 37098965
Significance: We describe the regulation of splicing factor SRSF1 expression in the context of pancreas cell identity, plasticity, and inflammation. SRSF1 protein downregulation is involved in a negative feedback cellular...
10.
Wan L, Kral A, Voss D, Krainer A
bioRxiv
. 2023 Apr;
PMID: 37066201
Aberrant alternative splicing is emerging as a cancer hallmark and a potential therapeutic target. It is the result of dysregulated splicing factors or genetic alterations in splicing-regulatory -elements. Targeting individual...